Market News & Trends
Roquette Announces Strategic Investment & Innovation Agreement With Beren Therapeutics P.B.C.
Roquette recently announce a strategic investment with Beren Therapeutics P.B.C., and the launch of an innovation agreement to expand the full potential of Beren’s cyclodextrin technologies and their medicinal….
Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease
Vega Therapeutics, Inc. recently announced the US FDA has granted the company orphan drug designation for VGA039 for the treatment of the rare bleeding disorder,…
AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration & Diabetic Macular Edema
AiViva Biopharma Inc. recently announced it has begun a Phase 1 trial and completed dosing the first cohort of patients diagnosed with wet age-related macular…
Oculis Announces Positive Top Line Results From DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema With OCS-01 Eye Drops
Oculis Holding AG recently announced positive top line results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 eye drops in Diabetic Macular…
NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors
NeuBase Therapeutics, Inc. recently announced a broad set of preclinical safety and efficiency data for its Stealth Editors development program that demonstrate the ability to achieve…
Circulating Tumor Cells Isolated With Unique TellDx Technology May Help Predict Response to Therapy in Patients With Progressive Metastatic Breast Cancer
TellBio, Inc. recently announced publication of data that show the utility of CTCs isolated with TellDx to assess sensitivity and potential clinical benefit from an alternative tolerable therapeutic option in a cohort of….
Sangamo Receives FDA Fast Track Designation for Fabry Disease Gene Therapy Product Candidate
Sangamo Therapeutics, Inc. recently announced the US FDA has granted Fast Track Designation to isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate…
Cell & Gene Therapy CDMO Targets North American Growth With Major US Acquisition
uBriGene is expanding into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from NASDAQ-listed company Mustang Bio, Inc. The cell & gene therapy (CGT) CDMO has an….
BD Launches World's First Spectral Cell Sorter With High-Speed Cell Imaging
BD (Becton, Dickinson and Company) recently announced the worldwide commercial launch of a new-to-world cell sorting instrument featuring two breakthrough technologies that enable researchers to…
Biodexa Pharmaceuticals Enters Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals
Biodexa Pharmaceuticals recently announced it has signed non-binding letter of intent to potentially acquire Varian Biopharmaceuticals, Inc., a private US precision oncology company developing….
Siren Biotechnology Launches to Pioneer Universal AAV Immuno-Gene Therapy for Cancer
Novel approach combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single transformative modality….
Sania Therapeutics Launches to Advance Novel Medicines for Neural Circuit Dysfunction
Sania Therapeutics, focused on developing genetic medicines for neural circuit dysfunction, recently launched by unveiling its suite of proprietary patented platforms at….
Elevar Therapeutics Submits NDA to FDA for Combination of Rivoceranib & Camrelizumab as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma
Elevar Therapeutics, Inc. recently announced it submitted an NDA to the US FDA for its investigational drug rivoceranib, an oral TKI, in combination with camrelizumab,…
Alliance Pharma & Drug Development Solutions Are Now Resolian
Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development Solutions, Ltd. (acquired in…
First on the Market: Safely Storing Deep-Cold Medications With Prefillable Polymer Syringes From SCHOTT Pharma
SCHOTT Pharma’s prefillable polymer syringes are a trailblazing solution for drug applications that need to be stored and transported on dry ice at temperatures approaching -100°C…..
Experic Adds Spray Drying Capabilities to Enhance Pharmaceutical Formulation & Development Services
Experic recently announced the addition of spray drying capabilities to support the formulation and development of biopharmaceuticals. The new spray drying services will be….
Bayer Receives Fast Track Designation for Asundexian Atrial Fibrillation Program
Bayer recently announced the US FDA has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and…
QSAM Biosciences & RLS Announce Clinical & Commercial Supply Agreement for Promising Clinical-Stage Metastatic & Primary Bone Cancer Treatment
QSAM Biosciences, Inc. and RLS (USA) Inc. recently announced a commercial supply and clinical dose preparation agreement for the therapeutic radiopharmaceutical drug candidate CycloSam (Samarium-153…
NurExone Granted US Patent for Technology & Drug Composition of Exo-PTEN, Designed for Treating Acute Spinal Cord Injuries
NurExone Biologic Inc. recently announced it has received an issue notification from the United States Patent and Trademark Office (USPTO) for US Patent NO. 11,648,260, granted for the period of 20 years from filing date until….
TILT Biotherapeutics Announces First Patient Dosed in Phase 1 Solid Tumors Trial Assessing Oncolytic Adenovirus TILT-123 in Combination With Checkpoint Inhibitor
TILT Biotherapeutics recently announced the first patient has been dosed in a Phase 1 trial of the company’s oncolytic adenovirus TILT-123. The multi-centre open-label, Phase…